What is Wedbush's Estimate for Chimerix FY2028 Earnings?

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush raised their FY2028 EPS estimates for shares of Chimerix in a report released on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $0.58 per share for the year, up from their prior forecast of $0.47. Wedbush has a "Outperform" rating and a $7.00 price target on the stock. The consensus estimate for Chimerix's current full-year earnings is ($0.99) per share.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Tuesday.

Chimerix Stock Performance

Chimerix stock traded down $0.01 during trading hours on Wednesday, reaching $5.16. 1,965,157 shares of the stock were exchanged, compared to its average volume of 1,658,660. The stock has a market cap of $464.45 million, a P/E ratio of -5.49 and a beta of 0.35. Chimerix has a 52-week low of $0.75 and a 52-week high of $5.53. The firm's 50 day moving average is $3.72 and its 200 day moving average is $1.92.

Insider Activity

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 20,760 shares of company stock worth $91,175 in the last 90 days. 13.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Chimerix

Hedge funds have recently modified their holdings of the stock. Deerfield Management Company L.P. Series C purchased a new stake in shares of Chimerix during the fourth quarter valued at approximately $13,124,000. Rosalind Advisors Inc. bought a new stake in shares of Chimerix in the fourth quarter worth $10,614,000. Millennium Management LLC increased its stake in shares of Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company's stock worth $8,900,000 after buying an additional 161,795 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company's stock worth $7,705,000 after buying an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new stake in shares of Chimerix in the fourth quarter worth $7,169,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.